ORIONS Money Stocks

[AugustaFriends]

iBio announces expansion of its intellectual property portfolio; allowance of patent for anthrax vaccines and further application of modulator platform (IBIO) 0.84 : Co announced that the US Patent Office has allowed patent application 11/706,576 entitled 'Bacillus anthracis Antigens, Vaccine Compositions, and Related Methods.' The claims cover compositions and methods for fusions of sequences of Bacillus anthracis antigens for protective antigen, lethal factor, and edema factor, and combinations thereof to LicKM, which is part of the Company's iBioModulator platform. Upon issue, this patent will add to iBio's iBioModulator portfolio that includes recently issued US patent 8,173,408 giving broad coverage of the iBioModulator system, and US patent 8,124,103 covering influenza antigens fused to LicKM.